Hydrofarm Holdings Group, Inc. (HYFM) · Oct 27, 2026 · Restructuring
$109M debt extinguished — ~$109M loan exchanged for preferred stock and warrants
Hydrofarm’s restructuring erases roughly $109M of debt and raises $8.3M, but the deal adds substantial dilution and lender control rights.
Hydrofarm is a hydroponics and controlled-environment-agriculture supplier trying to stabilize a business hit by industry oversupply, sharply lower sales, and a distressed balance sheet; its recent plan has centered on cost cuts, proprietary brands, asset sales, and lender negotiations.
The core balance-sheet problem is materially reduced. The company exchanged its roughly $109 million term-loan obligation for 27.5 million shares of Series 1 preferred stock plus warrants for up to 27.5 million common shares. The filing says the debt was “paid, discharged and satisfied in full,” removing the immediate secured-lender overhang and associated liens.
| Transaction | Amount / terms |
|---|---|
| Gross cash raised | $8.3 million before fees and expenses (Offering) |
| Common and pre-funded shares issued | 9.21 million common-equivalent shares at about $0.905 (Purchase Agreement) |
| Investor common warrants | 9.21 million shares at $0.78, expiring 5.5 years after issuance (Common Warrants) |
| Debt retired | Approximately $109 million principal, exchanged for preferred stock and lender warrants (Payoff Letter) |
| Lender preferred stock | 27.5 million shares, convertible at $1.00 per share after stockholder approval (Certificate of Designation) |
| Lender warrants | Up to 27.5 million common shares at $0.78, subject to stockholder approval (Payoff Letter) |
This is a survival financing, not a clean reset. Hydrofarm receives $8.3 million of gross cash for general corporate purposes, but the offering also creates 9.21 million investor warrants, placement-agent warrants equal to 8% of the securities sold, and a potentially very large lender equity claim. The cash improves near-term liquidity; the securities package makes the eventual ownership structure substantially more diluted if the warrants and preferred stock convert.
The deal also shifts influence toward the lenders. The lenders receive the right to designate one director immediately and up to three additional directors, subject to stockholder approval and Nasdaq limits. That is a meaningful governance concession in exchange for debt relief, while the preferred stock ranks ahead of common stock in liquidation and carries conversion economics tied to a $1.00 value.
Nasdaq risk is improved but not cleared. Hydrofarm says its pro forma stockholders’ equity exceeds Nasdaq’s $2.5 million threshold after the transactions, which directly addresses the equity deficiency that had triggered the hearing process. But the pro forma balance sheet is not included in the filing, and Nasdaq still has to accept the calculation while continuing to monitor the company’s other listing requirements.
Bottom line: This removes the company’s most immediate financing threat and gives Hydrofarm a better chance to remain listed, but it does so through a highly dilutive recapitalization that gives lenders substantial future equity and board influence. The direction was already telegraphed by the prior debt default and strategic-alternatives process; the new information is the scale and terms of the compromise.
Stockholder vote on lender conversions and warrants
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!